These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30160393)

  • 1. The burden of cardiovascular disease in patients with diabetes.
    Hudspeth B
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S268-S272. PubMed ID: 30160393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.
    Newman JD; Schwartzbard AZ; Weintraub HS; Goldberg IJ; Berger JS
    J Am Coll Cardiol; 2017 Aug; 70(7):883-893. PubMed ID: 28797359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular disease prevention in adults with type 2 diabetes mellitus according to the recent statement from the American Heart Association/American Diabetes Association].
    Avogaro A
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):5S-11. PubMed ID: 27030118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease in diabetes.
    Zhang PY
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2205-14. PubMed ID: 25070828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Dietary Strategies for Prevention of Atherosclerotic Cardiovascular Disease in Diabetes: Evidence and Recommendations.
    Liday C; Kirkpatrick C
    Curr Cardiol Rep; 2019 Oct; 21(11):132. PubMed ID: 31624930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus.
    Donaghue K; Jeanne Wong SL
    Curr Diabetes Rev; 2017; 13(6):533-543. PubMed ID: 28120713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic implications with newer agents to reduce cardiovascular risk in diabetes.
    McAdam-Marx C
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S279-S285. PubMed ID: 30160395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.
    Guo F; Hsieh E; Lv W; Han Y; Xie J; Li Y; Song X; Li T
    BMC Infect Dis; 2017 Apr; 17(1):287. PubMed ID: 28427339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal: The PICT2RE observational study.
    Cardoso H; Tavares Bello C; Andrade L; Sobral do Rosário F; Louro J; Nogueira C; Rodrigues E; Vieira NB; Carqueja T;
    Rev Port Cardiol; 2023 Apr; 42(4):319-330. PubMed ID: 36634764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes.
    Motairek I; Al-Kindi S
    Endocrinol Metab Clin North Am; 2023 Mar; 52(1):135-147. PubMed ID: 36754490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus: a cardiovascular disease.
    Candido R; Srivastava P; Cooper ME; Burrell LM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes.
    ; Shah RD; Braffett BH; Tryggestad JB; Hughan KS; Dhaliwal R; Nadeau KJ; Levitt Katz LE; Gidding SS
    J Diabetes Complications; 2022 Mar; 36(3):108123. PubMed ID: 35123868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the risk and nature of CVD the same in type 1 and type 2 diabetes?
    Duca L; Sippl R; Snell-Bergeon JK
    Curr Diab Rep; 2013 Jun; 13(3):350-61. PubMed ID: 23519720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study.
    Shore AC; Colhoun HM; Natali A; Palombo C; Östling G; Aizawa K; Kennbäck C; Casanova F; Persson M; Gooding K; Gates PE; Khan F; Looker HC; Adams F; Belch J; Pinnoli S; Venturi E; Morizzo C; Goncalves I; Ladenvall C; Nilsson J;
    J Intern Med; 2015 Sep; 278(3):291-302. PubMed ID: 25752315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in adolescents with type 2 diabetes mellitus.
    Apedo MT; Sowers JR; Banerji MA
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():519-23. PubMed ID: 12017226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review.
    Vaidya V; Gangan N; Sheehan J
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):487-97. PubMed ID: 25824591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care.
    Rennert NJ; Charney P
    Prim Care; 2003 Sep; 30(3):569-92. PubMed ID: 14692202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular diseases and risk factors knowledge and awareness in people with type 2 diabetes mellitus: a global evaluation.
    Saeedi P; Karuranga S; Hammond L; Kaundal A; Malanda B; Prystupiuk M; Matos P
    Diabetes Res Clin Pract; 2020 Jul; 165():108194. PubMed ID: 32389743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease.
    Ofori S; Dodiyi-Manuel S; Akpa MR
    J Clin Lipidol; 2017; 11(6):1441-1447. PubMed ID: 29050979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.